Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitazoxanide for COVID-19 Post-Exposure Prophylaxis
NCT04435314Phase 2Withdrawn
- Sponsor
- Azidus Laboratories Limited
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Nitazoxanide Arm with Placebo Arm (2 arms). Primary endpoint: Proportion of subjects with laboratory-confirmed COVID-19 at 28 days. Planned start Jun 2020; status: withdrawn.
02
Drugs
nitazoxanide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04435314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435314.